Is dabrafenib available in China?

Dabrafenib (Dabrafenib) The original drug entered the Chinese market through the regulations of the State Food and Drug Administration in December 2019. It is marketed and sold under the name of dabrafenib mesylate capsules, and can also be called Tafinlar. The original drug of dabrafenib has also entered the scope of Class B medical insurance through the relevant policies of the National Medical Insurance Administration. Only patients who meet the indications can be reimbursed, otherwise they will purchase the drug at their own expense.

Dabrafenib is a targeted cancer drug known in the glossary as a cancer growth blocker. The indications for domestic marketing include BRAF V600 mutation-positive unresectable or metastatic melanoma and its postoperative adjuvant treatment, and BRAF V600 mutation-positive metastatic non-small cell lung cancer patients. Dabrafenibcan be used alone or in combination with other drugs to increase the therapeutic effect, such as trametinib. A patient can be treated with dabrafenib as long as their cancer has a change in the BRAF gene, and doctors will check for the mutation before the patient starts taking the drug.

The original drug of dabrafenib on the domestic market is relatively expensive, and the price of each box of 50mg*120 capsules may be around 10,000 yuan. The Turkish version of the original drug Dabrafenib sold overseas, Specifications 75mg*120 capsules, may cost around 10,000 per box (the price may fluctuate due to exchange rates). There are also relatively cheap generics of dabrafenib sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, Specifications produced by Laos Pharmaceutical Factory The price of 75mg*120 tablets per box may be more than 4,000 yuan (the price may fluctuate due to exchange rates).